

SELL TP: Rs 2,080 | ¥ 16%

PIDILITE INDUSTRIES

Construction Materials

12 November 2021

Broad-based growth but sharp RM headwinds a drag

- Consolidated Q2 net revenue up 40% YoY to Rs 26.3bn. Like-to-like growth at 33% (ex-PAPL)
- Gross margin contracted 1,050bps YoY to 45.4% on account of sharp increase in VAM price to US\$ 2,071/mt vs. US\$ 765/mt
- Target multiple raised given growth traction but RM headwinds prompt earnings cut. Retain SELL; new Sep'22 TP at Rs 2,080 (vs. Rs 1,525)

Ruchitaa Maheshwari researchreport@bobcaps.in

Broad-based revenue growth: PIDI's consolidated Q2FY22 net revenue grew 40% YoY to Rs 26.3bn (33% on like-to-like basis which excludes PAPL). Consumer & Bazaar (C&B) segment revenue increased 40% YoY to Rs 21.3bn but segmental EBIT margin declined 750bps to 27.4%. The B2B segment grew 41% YoY to Rs 5.3bn with EBIT margin down 275bps YoY to 5%.

Strong RM headwinds: Gross margin contracted 1,050bps YoY (-370bps QoQ) as prices of key material VAM increased to US\$ 2,071/mt vs. US\$ 765/mt in Q2FY21 (US\$ 1,610/mt in Q1). A decline in employee cost/other expenses as a percentage of sales (-250bps/-170bps YoY) limited EBITDA margin contraction at 630bps YoY to 20.9%. EBITDA grew 7% YoY to Rs 5.5bn.

Standalone performance: Sales volume and mix growth stood at 25% YoY, with 25%/20% growth in C&B/B2B. Net sales grew 36% YoY to Rs 22.1bn. C&B revenue rose 35% YoY to Rs 18bn while EBIT margin contracted 825bps to 28.5%. B2B revenue grew 40% YoY to Rs 4.4bn with a 420bps margin decline to 9.7%. Gross/EBITDA margin contracted by 1,100bps/730bps YoY to 45.5%/21.6%.

Estimates trimmed: While PIDI has delivered strong, broad-based sales and earnings growth, we prune FY22/FY23 EPS estimates by 10%/3% given rising VAM prices (up from US\$ 2,071/mt in Q2 to spot levels of US\$ 2,300-2,400/mt). We expect spiraling input costs to sustain/peak in the near term leading to stressed margins. While PIDI has initiated calibrated price hikes during the quarter, these cover only ~75% of inflation. Management is consciously looking to absorb the partial impact given high volatility in input prices and near-term demand uncertainty.

Valuations stretched; maintain SELL: We remain positive on PIDI's long-term story given its strong presence in waterproofing and construction chemicals (first-mover advantage) and robust connect with trade channels. However, the stock looks overvalued at current levels of 78x FY23E EPS. We roll forward to a revised Sep'22 TP of Rs 2,080 (Rs 1,525 earlier), based on a 60x one-year forward P/E multiple (45x earlier), in line with the five-year median. SELL.

Key changes

rtoy onlangee		
Target	Rating	
A	< ▶	

Ticker/Price	PIDI IN/Rs 2,474
Market cap	US\$ 16.9bn
Free float	30%
3M ADV	US\$ 14.6mn
52wk high/low	Rs 2,532/Rs 1,501
Promoter/FPI/DII	70%/12%/18%


Source: NSE | Price as of 11 Nov 2021

Key financials

Y/E 31 Mar	FY21A	FY22E	FY23E
Total revenue (Rs mn)	72,927	89,662	1,03,920
EBITDA (Rs mn)	16,806	19,008	23,694
Adj. net profit (Rs mn)	11,339	12,773	16,113
Adj. EPS (Rs)	22.3	25.1	31.7
Consensus EPS (Rs)	22.3	26.5	33.1
Adj. ROAE (%)	22.6	21.8	25.0
Adj. P/E (x)	110.9	98.4	78.0
EV/EBITDA (x)	74.6	65.9	52.9
Adj. EPS growth (%)	(2.2)	12.7	26.1

Source: Company, Bloomberg, BOBCAPS Research

Stock performance



Source: NSE





Earnings call highlights

- Growth in Q2FY22 was broad-based across the C&B and B2B segments as well as
 in urban and rural geographies. C&B reported growth across all categories such as
 adhesives, construction chemicals and the DIY portfolio. B2B growth was led by
 continued momentum in industrial activities.
- The company continues to focus on rural/semi-urban markets for deeper product penetration.
- Prices of key input VAM have hardened from US\$ 765/mt in Q2FY21 to US\$ 2,071/mt in Q2FY22. The spot prices is US\$ 2,300-2,400/mt. Management expects prices to start cooling off in six months' time.
- PIDI has taken a calibrated price hike which will cover ~75% of the input cost inflation bearing in mind near-term demand uncertainty.
- The steep rise in raw material prices and supply chain disruptions have taken a significant toll on unorganised players. This has benefited organised players such as PIDI in terms of market share gains due to its strong supply chain network.
- Management is focused on profitable volume growth and has maintained its annual EBITDA margin guidance of 22-24%.
- Domestic subsidiaries in the C&B business returned to double-digit growth led by higher sales of premium products. Subsidiaries in the B2B business have improved sequentially on account of recovery in real estate and construction-related activities, though margin recovery will take longer due to the unabated commodity inflation.
- Subsidiary PAPL posted revenue of Rs 1.4bn with an EBITDA margin of ~35% during Q2. As per management, the raw material inputs are limited and hence the margin remained largely stable.
- In the international business, the Americas declined 20% YoY in Q2 on a higher previous-year base on account of pent-up demand and benefits passed by the Govt during Covid-19. The company saw modest revenue growth of 14% YoY in Asia due to lockdown restrictions in many countries. EBITDA margin for the region was impacted by 160bps YoY to 13.7% on account of input cost inflation. The Middle East reported 34% YoY revenue growth.
- The water-proofing business is growing at 40-50%. Management is working to educate consumers about the product benefits, create brand awareness and provide service.
- PIDI typically halts A&P spends one month before Diwali as the space is crowded with media advertisement and construction activity also slows down. Post Diwali, with resumption of construction activity, A&P will be higher.
- The company will incur capex at 4-6% of sales in subsequent years.



Fig 1 – Consolidated quarterly performance

(Rs mn)	Q2FY22	Q2FY21	YoY (%)	Q1FY22	QoQ (%)	H1FY22	H1FY21	YoY (%)
Net revenues	26,264	18,803	39.7	19,368	35.6	45,631	27,582	65.4
Raw Material Cost	14,339	8,284	73.1	9,857	45.5	24,197	12,369	95.6
Employee cost	2,731	2,421	12.8	2,806	(2.7)	5,537	4,578	20.9
Other expenses	3,697	2,972	24.4	3,229	14.5	6,926	4,845	43.0
EBITDA	5,496	5,126	7.2	3,476	58.1	8,972	5,790	55.0
EBITDA margin (%)	20.9	27.3	(634bps)	17.9	298bps	19.7	21.0	(133bps)
Depreciation and amortization	603	479	26.0	566	6.5	1,170	940	24.4
EBIT	4,893	4,648	5.3	2,910	68.2	7,802	4,850	60.9
EBIT Margin (%)	18.6	24.7	(609bps)	15.0	361bps	17.1	17.6	(49bps)
Net Interest expenses	124	87	42.9	96	28.5	220	177	24.0
Foreign exchange gain (loss), net	0	0	n.m.	0	n.m.	0	0	n.m.
Other income	139	217	(35.9)	61	127.1	200	417	(52.0)
EBT and except. Items	4,908	4,778	2.7	2,875	70.7	7,783	5,090	52.9
Exceptional items	0	0	n.m.	0	n.m.	0	0	n.m.
Earnings before tax	4,908	4,778	2.7	2,875	70.7	7,783	5,090	52.9
Income taxes	1,159	1,220	(5.0)	721	60.8	1,880	1,378	36.4
Income tax as % of PBT	23.6	25.5	(191bps)	25.1	(146bps)	24.2	27.1	(292bps)
Earnings after tax	3,749	3,558	5.4	2,154	74.1	5,902	3,712	59.0
Profit in associate company	7	6	6.6	23	(71.5)	29	11	171.3
Minority interest (expense) income	(9)	(0)	n.m.	24	n.m.	16	109	(85.8)
Net income (loss) adjusted	3,747	3,564	5.1	2,201	70.2	5,947	3,832	55.2
Non-recurring items	0.0	0.0	NM	0.0	NM	0.0	0.0	NM
Net income (loss), reported	3,747	3,564	5.1	2,201	70.2	5,947	3,832	55.2

Source: Company, BOBCAPS Research

Fig 2 – Consolidated segmental performance

(Rs mn)	Q2FY22	Q2FY21	YoY (%)	Q1FY22	QoQ (%)	H1FY22	H1FY21	YoY (%)
Revenue								
Consumer & Bazaar Products	21,304	15,277	39.5	14,862	43.3	36,167	22,297	62.2
Business to Business	5,324	3,771	41.2	4,820	10.4	10,144	5,653	79.4
Others	146	72	103.9	99	47.4	245	90	173.1
Total	26,774	19,119	40.0	19,782	35.3	46,555	28,040	66.0
Less: Inter Segment revenue	(510)	(316)	61.4	(414)	23.4	(924)	(458)	101.6
Net revenues	26,264	18,803	39.7	19,368	35.6	45,631	27,582	65.4
EBIT								
Consumer & Bazaar Products	5,827	5,324	9.5	3,704	57.3	9,531	6,644	43.5
Business to Business	263	290	(9.4)	420	(37.4)	683	63	977.1
Others	(8)	8	n.m.	6	(230.0)	(2)	(27)	(93.4)
Total	6,082	5,621	8.2	4,131	47.2	10,212	6,680	52.9
EBIT Margin (%)								
Consumer & Bazaar Products	27.4	34.8	(750bps)	27.1	23bps	26.4	29.8	(344bps)
Business to Business	4.9	7.7	(275bps)	9.8	(486bps)	6.7	1.1	561bps
Total	23.2	29.9	(674bps)	23.4	(24bps)	22.4	24.2	(184bps)

Source: Company, BOBCAPS Research



Fig 3 – Standalone quarterly performance

(Rs mn)	Q2FY22	Q2FY21	YoY (%)	Q1FY22	QoQ (%)	H1FY22	H1FY21	YoY (%)
Net revenues	22,134	16,302	35.8	16,261	36.1	38,395	24,026	59.8
Raw material exp	12,052	7,090	70.0	8,256	46.0	20,309	10,603	91.5
Employee exp	2,230	1,954	14.2	2,293	(2.8)	4,524	3,671	23.2
Other exp	3,062	2,541	20.5	2,716	12.7	5,778	4,080	41.6
EBITDA	4,790	4,719	1.5	2,995	59.9	7,785	5,673	37.2
EBITDA margin (%)	21.6	28.9	(730bps)	18.4	322bps	20.3	23.6	(333bps)
Depreciation and amortization	443	359	23.4	405	9.6	848	707	19.9
EBIT	4,347	4,359	(0.3)	2,590	67.8	6,937	4,966	39.7
EBIT Margin (%)	19.6	26.7	(710bps)	15.9	371bps	18.1	20.7	(260bps)
Net Interest expenses	443	30	1368.2	63	609.4	506	64	694.2
Other income	164	225	(27.1)	1,020	(83.9)	1,184	422	180.9
PBT	4,067	4,554	(10.7)	3,548	14.6	7,615	5,324	43.1
Income taxes	1,721	1,162	48.1	663	159.6	2,384	1,364	74.8
Income tax as % of PBT	42.3	25.5	1681bps	18.7	2364bps	31.3	25.6	569bps
Earnings after tax, adjusted	2,346	3,392	(30.8)	2,885	(18.7)	5,231	3,960	32.1
Extraordinary	0	(5)	(100.0)	0	-	0	(5)	(100.0)
Net income (loss), reported	2,346	3,388	(30.8)	2,885	(18.7)	5,231	3,955	32.3

Source: Company, BOBCAPS Research


Fig 4 – Standalone segmental performance

(Rs mn)	Q2FY22	Q2FY21	YoY (%)	Q1FY22	QoQ (%)	H1FY22	H1FY21	YoY (%)
Revenue								
Consumer & Bazaar Products	18,026	13,352	35.0	12,522	44.0	30,549	19,497	56.7
Business to Business	4,394	3,150	39.5	3,961	10.9	8,356	4,834	72.9
Others	146	72	103.9	99	47.4	245	90	173.1
Total	22,566	16,574	36.2	16,583	36.1	39,149	24,420	60.3
Less: Inter Segment revenue	(432)	(272)	59.1	(322)	34.3	(754)	394	(291.6)
Net revenues	22,134	16,302	35.8	16,261	36.1	38,395	24,814	54.7
EBIT								
Consumer & Bazaar Products	5,143	4,911	4.7	3,295	56.1	8,437	6,381	32.2
Business to Business	426	438	(2.7)	541	(21.2)	967	494	96.0
Others	(8)	(11)	n.m.	6	(230.0)	(2)	(27)	-93.4
Total	5,561	5,338	4.2	3,842	44.8	9,403	6,847	37.3
EBIT Margin (%)								
Consumer & Bazaar Products	28.5	36.8	(825bps)	29.6	(107bps)	27.6	32.7	(511bps)
Business to Business	9.7	13.9	(421bps)	14.4	(470bps)	11.6	10.2	137bps
Others	(5.3)	(15.1)	976bps	8.1	(1345bps)	(0.7)	(30.5)	2973bps
Total	25.1	32.7	(762bps)	26.5	(134bps)	24.5	27.6	(311bps)

Source: Company, BOBCAPS Research




Fig 5 - Standalone revenue growth




Source: Company, BOBCAPS Research

Fig 6 – Standalone EBITDA margin




Source: Company, BOBCAPS Research

Fig 7 - Standalone volume growth




Source: Company, BOBCAPS Research

Fig 8 - Consolidated revenue growth




Source: Company, BOBCAPS Research

Fig 9 - Consolidated revenue break-up



Source: Company, BOBCAPS Research

Fig 10 - Consolidated EBITDA margin



Source: Company, BOBCAPS Research



Valuation methodology

While PIDI has delivered strong, broad-based sales and earnings growth, we prune FY22/FY23 EPS estimates by 10%/3% given rising VAM prices (up from US\$ 2,071/mt in Q2 to spot levels of US\$ 2,300-2,400/mt). We expect spiraling input costs to sustain/peak in the near term leading to stressed margins. While PIDI has initiated calibrated price hikes during the quarter, these cover only ~75% of inflation. Management is consciously looking to absorb the partial impact given high volatility in input prices and near-term demand uncertainty.

We remain positive on PIDI's long-term story given its strong presence in waterproofing and construction chemicals (first-mover advantage) and robust connect with trade channels. However, the stock looks overvalued at current levels of 78x FY23E EPS. We roll forward to a revised Sep'22 TP of Rs 2,080 (Rs 1,525 earlier), based on a 60x one-year forward P/E multiple (45x earlier), in line with the five-year median. Retain SELL.

Fig 11 - Revised estimates

(Do)	Rs mn) New			Old			Change (%)		
(RS mn)	FY22E	FY23E	23E FY24E FY2	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E
Revenue	89,662	1,03,920	1,19,726	89,662	1,03,920	1,19,726	-	-	-
EBITDA	19,008	23,694	28,016	20,891	24,213	28,016	(9)	(2.1)	-
EBITDA %	21.2	22.8	23.4	23.3	23.3	23.4	(210bps)	(50bps)	-
PAT	12,773	16,113	19,117	14,160	16,547	19,169	(9.8)	(2.6)	(0.3)
EPS	25.1	31.7	37.6	27.9	32.6	37.7	(9.9)	(2.7)	(0.2)

Source: BOBCAPS Research

Fig 12 - Key assumptions

Parameter	FY21	FY22E	FY23E	FY24E
Consumer & Bazaar Products (Rs mn)	58,089	69,707	80,163	91,386
Growth (%)	4.2	20.0	15.0	14.0
Business to Business (Rs mn)	15,754	19,377	23,093	27,576
Growth (%)	(12.3)	23.0	19.2	19.4

Source: Company, BOBCAPS Research

Fig 13 - Peer comparison

0	Tielee	Datin	Detine Target	Revenue CAGR	Revenue CAGR EPS (Rs)		ROE (%)		Target
Company	Ticker	Rating	Price (Rs)	FY21-23E (%)	FY22E	FY23E	FY22E	FY23E	P/E (x)
Kajaria Ceramics	KJC IN	HOLD	1,393	21.5	22.8	29.6	18.9	23.3	47
Greenpanel Industries	GREENP IN	HOLD	395	27.6	14.1	18.3	21.1	22.1	20
Century Plyboard	CPBI IN	HOLD	630	19.5	12.1	15.1	19.9	20.5	37
Cera Sanitaryware	CRS IN	HOLD	5,893	17.1	109.8	134.9	15.4	16.9	40
Astral	ASTRA IN	SELL	1,210	16.3	20.2	25.2	20.3	22.6	48
Finolex Ind	FNXP IN	HOLD	185	4.2	7.3	7.5	13.9	13.2	24
Supreme Ind	SI IN	BUY	2,735	22.7	76.2	91.2	28.5	29.9	30
Pidilite industries	PIDI IN	SELL	2.080	19.4	25.1	31.7	21.8	25.0	60
Asian Paints*	APNT IN	NR	NA	12.9	38.5	47.3	27.1	29.4	NA

Source: BOBCAPS Research

PIDILITE INDUSTRIES



Key risks

Key upside risks to our estimates are:

- Sharp decline in raw material prices: Any sudden, steep fall in RM prices, especially for crude-linked products, could drive above-expected margins.
- Above-expected pickup in housing activity: A stronger revival in the housing market than anticipated can take growth ahead of estimates.



Financials

Y/E 31 Mar (Rs mn)	FY20A	FY21A	FY22E	FY23E	FY24E
Total revenue				1,03,920	
	72,945	72,927	89,662	· · ·	1,19,726
EBITDA	15,760	16,806	19,008	23,694	28,016
Depreciation	(1,699)	(2,007)	(2,242)	(2,598)	(2,993)
EBIT	14,061	14,800	16,767	21,096	25,023
Net interest inc./(exp.)	(336)	(372)	(180)	(135)	(60)
Other inc./(exp.)	396	794	699	852	918
Exceptional items	0	0	0	0	0
EBT	15,219	15,221	17,286	21,813	25,881
Income taxes	(3,477)	(3,964)	(4,494)	(5,671)	(6,729)
Extraordinary items	(552)	(36)	0	0	0
Min. int./Inc. from assoc.	(26)	91	(18)	(28)	(35)
Reported net profit	11,164	11,312	12,773	16,113	19,117
Adjustments	426	27	0	0	0
Adjusted net profit	11,590	11,339	12,773	16,113	19,117
Balance Sheet					
Y/E 31 Mar (Rs mn)	FY20A	FY21A	FY22E	FY23E	FY24E
Accounts payables	6,210	10,067	9,629	10,819	12,333
Other current liabilities	9,185	12,958	12,458	11,958	11,458
Provisions	735	829	959	1,109	1,259
Debt funds	1,691	2,139	3,000	850	850
Other liabilities	823	3,980	3,980	3,980	3,980
	508	508	508	508	508
Equity capital		55,421			
Reserves & surplus	44,048	•	60,636	67,213	75,017
Shareholders' fund	44,556	55,930	61,144	67,721	75,525
Total liab. and equities	65,357	88,304	93,635	98,983	1,08,047
Cash and cash eq.	7,033	4,515	8,376	9,923	13,212
Accounts receivables	10,885	13,210	13,511	15,659	18,041
Inventories	9,295	12,342	12,037	12,171	13,875
Other current assets	10,157	9,190	10,170	11,115	12,146
Investments	7,197	1,765	1,810	1,863	1,924
Net fixed assets	12,890	14,428	39,450	39,969	40,568
CWIP	2,593	2,939	2,939	2,939	2,939
Intangible assets	5,178	29,751	5,178	5,178	5,178
Deferred tax assets, net	130	166	166	166	166
Other assets	0	0	0	0	
Total assets	65,357	88,304	93,635	98,983	1,08,047
Cash Flows					
Y/E 31 Mar (Rs mn)	FY20A	FY21A	FY22E	FY23E	FY24E
Cash flow from operations	13,474	14,866	13,475	16,538	18,314
Capital expenditures	(4,687)	(24,088)	(2,690)	(3,118)	(3,592)
Change in investments	4,317	5,433	(46)	(53)	(61)
Other investing cash flows	33	1,203	0	Ó	Ċ
Cash flow from investing	(337)	(17,452)	(2,736)	(3,170)	(3,652)
Equities issued/Others	0	0	0	0	(4,44
Debt raised/repaid	581	448	861	(2,150)	Č
Interest expenses	(336)	(372)	(180)	(135)	(60)
Dividends paid	(8,254)	(7)	(7,559)	(9,536)	(11,313)
zao paia	0,204)	0	0	0	(11,010)
Other financing cash flows					
Other financing cash flows					(11 372)
Other financing cash flows Cash flow from financing Chg in cash & cash eq.	(8,009) 5,128	69 (2,517)	(6,878) 3,861	(11,821) 1,547	(11,373)

Per Share	E\/00 <i>t</i>	E)/04 f	E)/00E	E)/00E	E)/0 /=
Y/E 31 Mar (Rs)	FY20A	FY21A	FY22E	FY23E	FY24E
Reported EPS	22.0	22.3	25.1	31.7	37.6
Adjusted EPS	22.8	22.3	25.1	31.7	37.6
Dividend per share	13.5	8.5	11.8	14.9	17.7
Book value per share	87.7	110.1	120.3	133.3	148.6
Valuations Ratios					
Y/E 31 Mar (x)	FY20A	FY21A	FY22E	FY23E	FY24E
EV/Sales	17.2	17.2	14.0	12.1	10.4
EV/EBITDA	79.7	74.6	65.9	52.9	44.6
Adjusted P/E	108.5	110.9	98.4	78.0	65.8
P/BV	28.2	22.5	20.6	18.6	16.6
DuDont Analysis					
DuPont Analysis Y/E 31 Mar (%)	FY20A	FY21A	FY22E	FY23E	FY24E
Tax burden (Net profit/PBT)	76.2	74.5	73.9	73.9	73.9
Interest burden (PBT/EBIT)	108.2	102.8	103.1	103.4	103.4
EBIT margin (EBIT/Revenue)	19.3	20.3	18.7	20.3	20.9
Asset turnover (Rev./Avg TA)	117.2	94.9	98.6	107.9	115.7
Leverage (Avg TA/Avg Equity)	1.4	1.5	1.6	1.5	1.4
Adjusted ROAE	26.9	22.6	21.8	25.0	26.7
Ratio Analysis					
Y/E 31 Mar	FY20A	FY21A	FY22E	FY23E	FY24E
YoY growth (%)					
Revenue	3.0	0.0	22.9	15.9	15.2
EBITDA	15.2	6.6	13.1	24.6	18.2
EBITDA Adjusted EPS	15.2 30.2	6.6 (2.2)	13.1 12.7	24.6 26.1	
Adjusted EPS Profitability & Return ratios (%)					
Adjusted EPS Profitability & Return ratios (%)					18.6
Adjusted EPS Profitability & Return ratios (%) EBITDA margin EBIT margin	30.2	(2.2)	12.7	26.1	18.6
Adjusted EPS Profitability & Return ratios (%) EBITDA margin EBIT margin	30.2 21.6	23.0	12.7	26.1	18.6 23.4 20.9
Adjusted EPS Profitability & Return ratios (%) EBITDA margin EBIT margin	30.2 21.6 19.3	(2.2) 23.0 20.3	12.7 21.2 18.7	26.1 22.8 20.3	23.4 20.9 16.0
Adjusted EPS Profitability & Return ratios (%) EBITDA margin EBIT margin Adjusted profit margin	30.2 21.6 19.3 15.9	(2.2) 23.0 20.3 15.5	12.7 21.2 18.7 14.2	26.1 22.8 20.3 15.5	18.6 23.4 20.9 16.0 26.7
Adjusted EPS Profitability & Return ratios (%) EBITDA margin EBIT margin Adjusted profit margin Adjusted ROAE	21.6 19.3 15.9 26.9	23.0 20.3 15.5 22.6	12.7 21.2 18.7 14.2 21.8	26.1 22.8 20.3 15.5 25.0	23.4 20.9 16.0 26.7
Adjusted EPS Profitability & Return ratios (%) EBITDA margin EBIT margin Adjusted profit margin Adjusted ROAE ROCE	21.6 19.3 15.9 26.9	23.0 20.3 15.5 22.6	12.7 21.2 18.7 14.2 21.8	26.1 22.8 20.3 15.5 25.0	18.6 23.4 20.9 16.0 26.7 24.7
Adjusted EPS Profitability & Return ratios (%) EBITDA margin EBIT margin Adjusted profit margin Adjusted ROAE ROCE Working capital days (days)	21.6 19.3 15.9 26.9 23.3	(2.2) 23.0 20.3 15.5 22.6 20.1	12.7 21.2 18.7 14.2 21.8 19.5	26.1 22.8 20.3 15.5 25.0 22.7	18.6 23.4 20.9 16.0 26.7 24.7
Adjusted EPS Profitability & Return ratios (%) EBITDA margin EBIT margin Adjusted profit margin Adjusted ROAE ROCE Working capital days (days) Receivables	30.2 21.6 19.3 15.9 26.9 23.3	(2.2) 23.0 20.3 15.5 22.6 20.1	12.7 21.2 18.7 14.2 21.8 19.5	26.1 22.8 20.3 15.5 25.0 22.7	18.2 18.6 23.4 20.9 16.0 26.7 24.7 51 84
Adjusted EPS Profitability & Return ratios (%) EBITDA margin EBIT margin Adjusted profit margin Adjusted ROAE ROCE Working capital days (days) Receivables Inventory	30.2 21.6 19.3 15.9 26.9 23.3 54 100 38	(2.2) 23.0 20.3 15.5 22.6 20.1 60 117	12.7 21.2 18.7 14.2 21.8 19.5 54 101 51	22.8 20.3 15.5 25.0 22.7 51 90 47	18.6 23.4 20.9 16.0 26.7 24.7 51 84
Adjusted EPS Profitability & Return ratios (%) EBITDA margin EBIT margin Adjusted profit margin Adjusted ROAE ROCE Working capital days (days) Receivables Inventory Payables	30.2 21.6 19.3 15.9 26.9 23.3 54	(2.2) 23.0 20.3 15.5 22.6 20.1 60 117	12.7 21.2 18.7 14.2 21.8 19.5	26.1 22.8 20.3 15.5 25.0 22.7 51 90	18.6 23.4 20.9 16.0 26.7 24.7

Source: Company, BOBCAPS Research | Note: TA = Total Assets

2.1

41.8

(0.1)

1.5

39.8

0.0

1.9

93.2

(0.1)

2.0

156.6

(0.1)

2.3

420.6

(0.2)

Current ratio

Net interest coverage ratio

Adjusted debt/equity



Disclaimer

Recommendation scale: Recommendations and Absolute returns (%) over 12 months

BUY - Expected return >+15%


HOLD - Expected return from -6% to +15%

SELL - Expected return <-6%

Note: Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

Ratings and Target Price (3-year history): PIDILITE INDUSTRIES (PIDI IN)



B - Buy, H - Hold, S - Sell, A - Add, R - Reduce

Rating distribution

As of 31 October 2021, out of 105 rated stocks in the BOB Capital Markets Limited (BOBCAPS) coverage universe, 52 have BUY ratings, 25 have HOLD ratings, 6 are rated ADD*, 2 are rated REDUCE* and 20 are rated SELL. None of these companies have been investment banking clients in the last 12 months. (*Our ADD and REDUCE ratings are in the process of being migrated to the new recommendation structure.)

Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOBCAPS.

General disclaimers

BOBCAPS is engaged in the business of Institutional Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS has obtained registration as a Research Entity under SEBI (Research Analysts) Regulations, 2014, having registration No.: INH000000040 valid till 03 February 2025. BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017. BOBCAPS CIN Number: U65999MH1996GOI098009.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

PIDILITE INDUSTRIES



This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities —that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may act as market makers or assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

In the US, this material is only for Qualified Institutional Buyers as defined under rule 144(a) of the Securities Act, 1933. No part of this document may be distributed in Canada or used by private customers in the United Kingdom.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company in the past 12 months. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company.

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.